hi_老虎社区_美港股上老虎

zhaooa
2021-06-29

J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET

BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single

J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":159185668,"tweetId":"159185668","gmtCreate":1624948600554,"gmtModify":1633946614343,"author":{"id":3573730312795304,"idStr":"3573730312795304","authorId":3573730312795304,"authorIdStr":"3573730312795304","name":"zhaooa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>hi</p></body></html>","htmlText":"<html><head></head><body><p>hi</p></body></html>","text":"hi","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/159185668","repostId":2147859758,"repostType":4,"repost":{"id":"2147859758","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624946364,"share":"https://www.laohu8.com/m/news/2147859758?lang=&edition=full","pubTime":"2021-06-29 13:59","market":"us","language":"en","title":"J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2147859758","media":"Reuters","summary":"BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single","content":"<p>BENGALURU, June 29 (Reuters) - Johnson &amp; Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.</p>\n<p>J&amp;J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.</p>\n<p>In late May, India said it would scrap local trials altogether for \"well-established\" vaccines manufactured in other countries.</p>\n<p>The U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()</p>\n<p>Over 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.</p>\n<p>Experts have said widespread vaccination remains <a href=\"https://laohu8.com/S/AONE\">one</a> of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.</p>\n<p>J&amp;J did not immediately respond to a Reuters request for comment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J scraps India COVID-19 vaccine trial, aims to accelerate availability - ET\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-29 13:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BENGALURU, June 29 (Reuters) - Johnson &amp; Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.</p>\n<p>J&amp;J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.</p>\n<p>In late May, India said it would scrap local trials altogether for \"well-established\" vaccines manufactured in other countries.</p>\n<p>The U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()</p>\n<p>Over 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.</p>\n<p>Experts have said widespread vaccination remains <a href=\"https://laohu8.com/S/AONE\">one</a> of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.</p>\n<p>J&amp;J did not immediately respond to a Reuters request for comment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147859758","content_text":"BENGALURU, June 29 (Reuters) - Johnson & Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India and is looking at ways to accelerate its availability in the country, the Economic Times reported on Tuesday, citing a company spokesperson.\nJ&J said in April it was in talks with India's government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.\nIn late May, India said it would scrap local trials altogether for \"well-established\" vaccines manufactured in other countries.\nThe U.S.-based drugmaker is exploring how to accelerate the availability of its vaccine in India, the Economic Times report said. ()\nOver 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.\nExperts have said widespread vaccination remains one of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.\nJ&J did not immediately respond to a Reuters request for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":447,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}